Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence F Eichenfield

Showing results (301-310 of 377) with videos related to

Pageof 38
Sort By:
Journal of the American Academy of Dermatology|June 17, 2017
Evidence-based recommendations for the management of acne fulminans and its variantsTanya Greywal, Andrea L Zaenglein, Hilary E Baldwin, et al.
Science Advances|January 6, 2023
Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteriaJordan Zeldin, Prem Prashant Chaudhary, Jacquelyn Spathies, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
American Journal of Public Health|February 3, 2007
Promoting sun safety among US Postal Service letter carriers: impact of a 2-year interventionJoni A Mayer, Donald J Slymen, Elizabeth J Clapp, et al.
The Journal of Investigative Dermatology|March 22, 2003
Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlationsGabriele Richard, Nkecha Brown, Fatima Rouan, et al.
Dermatology and Therapy|February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 StudiesAndrew Blauvelt, Leon Kircik, Eric L Simpson, et al.
The British Journal of Dermatology|July 1, 2026
Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 yearElaine C Siegfried, Eulalia Baselga, Marlies de Graaf, et al.
Current Medical Research and Opinion|December 3, 2024
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD RegistryMichael A Haft, Keith D Knapp, Ami Claxton, et al.
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
Pageof 38

Showing results (301-310 of 377) with videos related to

Sort By:
Pageof 38
Journal of the American Academy of Dermatology|June 17, 2017
Evidence-based recommendations for the management of acne fulminans and its variantsTanya Greywal, Andrea L Zaenglein, Hilary E Baldwin, et al.
Science Advances|January 6, 2023
Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteriaJordan Zeldin, Prem Prashant Chaudhary, Jacquelyn Spathies, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
American Journal of Public Health|February 3, 2007
Promoting sun safety among US Postal Service letter carriers: impact of a 2-year interventionJoni A Mayer, Donald J Slymen, Elizabeth J Clapp, et al.
The Journal of Investigative Dermatology|March 22, 2003
Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlationsGabriele Richard, Nkecha Brown, Fatima Rouan, et al.
Dermatology and Therapy|February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 StudiesAndrew Blauvelt, Leon Kircik, Eric L Simpson, et al.
The British Journal of Dermatology|July 1, 2026
Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 yearElaine C Siegfried, Eulalia Baselga, Marlies de Graaf, et al.
Current Medical Research and Opinion|December 3, 2024
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD RegistryMichael A Haft, Keith D Knapp, Ami Claxton, et al.
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
Pageof 38